European Journal of Heart Failure · 2022 · 52 citations · 40 references
MedicineCardiologyInternal MedicineClinical CardiologyCardiovascular DiseaseCardiovascular EpidemiologyHeart FailureAcute Heart Failure ManagementCardiac Outcome AssessmentHeart Failure EpidemiologyHeart Failure Hemodynamic EvaluationLeft Ventricular Diastolic DysfunctionLeft Ventricular Ejection Fraction DeclineSystolic DysfunctionVentricular Ejection Fraction Assessment
AIM: We aimed to evaluate clinical characteristics and 1-year outcomes in hospitalized patients with heart failure with preserved ejection fraction (HFpEF) from China. Factors associated with outcomes (hospitalization for HF [HHF] and cardiovascular [CV] death) were assessed. METHOD AND RESULTS: Data were from the China Cardiovascular Association (CCA) Database-HF Center Registry. Between January 2017 and June 2021, 41 708 hospitalized HFpEF patients with 1-year follow-up from 481 CCA Database-HF Center certified secondary and tertiary hospitals across overall 31 provinces of mainland China were included in this study. Of study participants (mean age 72.2 years, 49.3% female), 18.2% had HHF in prior 1 year and 55.8% had New York Heart Association class III/IV. Median left ventricular ejection fraction was 59%. Ischaemia (26.6%), infection (14.4%) and arrhythmia (10.5%) were the three most common precipitating factors for index HHF. Nearly 67.4% had ≥3 comorbidities. Hypertension (65.2%), coronary heart disease (60.3%) and atrial fibrillation (41.2%) were the three most common comorbidities. Device and medication therapy non-compliance with current HF guideline recommendation was observed. The 1-year rate of clinical outcomes was 16.4%, the 1-year rate of HHF was 13.6% and CV death was 3.1%. Factors associated with clinical outcomes included HHF in prior 1 year, serum level of sodium <135 mmol/L and N-terminal pro-B-type natriuretic peptide >1800 pg/ml. CONCLUSION: Patients with HFpEF from China were characterized by high comorbid burden and high 1-year risk of HHF and CV death. Immediate efforts are needed to improve HFpEF management in China.
40
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker, Javed Butler, Gerasimos Filippatos et al. · New England Journal of Medicine · 2021 · 4.6K citations · Full text
Medicine, Cardiology, Pharmacology +14
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt, Marc A. Pfeffer, Susan F. Assmann et al. · New England Journal of Medicine · 2014 · 2.7K citations · Full text
Medicine, Cardiology, Pharmacology +16